Regional Radiochemotherapy Using In Situ Hydrogel

Azhdarinia, Ali; Yang, David J.; Yu, Dongfang; Mendez, Richard; Oh, Chang-Sok; Kohanim, Saady; Bryant, Jerry; Kim, E. Edmund

doi:10.1007/s11095-005-2594-7

Cited by 37 publications

(15 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition to assessing molecular targets, development of 99m Tc-agents may be useful in planning internal targeted radionuclide therapy with betaemitting radionuclides such as 188 Re. 188 Re has attractive characteristics for imaging and potential therapeutic use because of its high -energy (2.1 MeV), short physical halflife (16.9 hr) and 155 keV -ray emission for dosimetric and imaging purposes [28]. The short half-life of 188 Re allows for higher doses compared with long-lived radionuclides.…”

Section: Technology Developmentmentioning

confidence: 99%

Challenges and Opportunities in Molecular Imaging

Yang

Chanda

Sims‐Mourtada

et al. 2008

CMIR

Self Cite

View full text Add to dashboard Cite

Molecular imaging research has been focused on identification of tumor specific markers and the application of these markers for evaluation of patient response to radiation therapy, chemotherapy or chemo/radiotherapy. Though the opportunities are involved in molecule in licensing, yet, the challenges involves in regulatory compliance in investigative new drugs such as chemistry, manufacturing, control, pre-clinical pharmacology/toxicology and clinic protocol management. In this article, we reviewed the opportunities and challenges in molecular imaging using generator produced isotopes. 99m Tc (technetium-99m), 68 Ga (gallium-68) and 188 Re (rhenium-188) are generator-produced isotopes which are readily-accessible and affordable. These generator produced isotopes were developed to label molecular targets for prediction of therapeutic response, monitoring tumor response to treatment and differential diagnosis. 188 Re is a therapeutic radionuclide which can be used to target tumors and deliver lethal radiation due to high-energy -emissions. Challenges and opportunities in molecular imaging involving drug discovery, validation, intellectual property in licensing and regulatory compliance are discussed.

show abstract

Section: Technology Developmentmentioning

confidence: 99%

Challenges and Opportunities in Molecular Imaging

Yang

Chanda

Sims‐Mourtada

et al. 2008

CMIR

Self Cite

View full text Add to dashboard Cite

show abstract

“…[17] A sodium alginate/calcium chloride hydrogel has been used for drug-delivery applications and drugs like cisplatin along with radiation ( 188 Re) have been used to provide combined therapeutic modalities. [3] The uniqueness of this hydrogel lies in the chemical properties associated with the crosslinking agent, calcium chloride, that performs a dual role of forming a complex with 188 Re and crosslinking with sodium alginate. This leads to [70] gel formation and slow-release of cisplatin coupled with trapping of 188 Re at the site of injection.…”

Section: Alginatesmentioning

confidence: 99%

“…[1] . Several strategies used to achieve this goal comprise of solvent removal [2] , in situ crosslinking, [3,4] and temperature-responsive polymeric systems. [5][6][7] Rapidly growing research and development into polymeric materials has played a vital role in the progress of this technology, as is shown by the increasing number of publications and patents in this area.…”

Section: Introductionmentioning

confidence: 99%

“…On the basis of the mechanism of solidification, these injectable implant systems can be divided into six categories, namely: 1) thermoplastic pastes, 2) in situ crosslinked systems, 3) in situ precipitation, 4) thermally induced gelling systems, 5) in situ solidifying organogels, and 6) hydrophobic fatty acid-based injectable pastes. Each system offers its own advantages but at the same they suffer from certain limitations.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Biodegradable Injectable In Situ Depot‐Forming Drug Delivery Systems

Chitkara

Shikanov

Kumar

et al. 2006

Macromolecular Bioscience

View full text Add to dashboard Cite

The scope of drug-delivery systems has expanded significantly in recent years providing new ways to deliver life saving therapeutics to patients. The development of new injectable drug-delivery systems has provided new vistas and opened up unexplored horizons in the field of science, particularly in controlled drug delivery since these systems possess unique advantages over traditional ones, which include ease of application, and localized and prolonged drug delivery. In the past few years, an increasing number of such systems has been reported in the literature for various biomedical applications, including drug delivery, cell encapsulation, and tissue repair. These are injectable fluids that can be introduced into the body in a minimally invasive manner prior to solidifying or gelling within the desired site. For this purpose both natural (chitosan, alginates) as well as synthetic polymers (PEGylated polyesters, ricinoleic acid-based polymers) have been utilized. These systems have been explored widely for the delivery of various therapeutic agents ranging for anti-neoplastic agents like paclitaxel to proteins and peptides such as insulin, almost covering every segment of the pharmaceutical field. This manuscript focuses on the recent advancements in the area of in situ forming biodegradable polymeric drug-delivery systems.

show abstract

“…XRT can be achieved using an external beam radiation source, an approach that is limited only for patients with operable tumours. Also, XRT can be achieved using brachytherapy seeds which localizes the radioactive isotope near or within the tumour tissue in order to minimize the damage of surrounding tissues 12 . Re was attempted to evaluate the possibility of its use as a radiotherapeutic agent or in a combination with 5-Aza for radiochemotherapeutic effect.…”

Section: Introductionmentioning

confidence: 99%